ライフサイエンスコーパス: type III

1 ype I), IFN-gamma (type II), and IFN-lambda (type III).

2 avage is required to allow signaling of NRG1 type III.

3 I, 17 (26.2%) as type II, and 21 (32.4%) as type III.

4 st common phenotype was type I (50.3%), with type III (29.6%), type II (14.5%) and type IV (5.7%).

5 Type I: 6, Type 2: 6, Type III: 6, Type IV: 11, Type V: 4.

6 rRNA maturation and establish a link between Type III-A CRISPR-Cas immunity and central nucleic acid

7 targeting by the Staphylococcus epidermidis type III-A CRISPR-Cas system does not require PAM or see

8 Staphylococcus epidermidis harbours a Type III-A CRISPR-Cas system that encodes the Cas10-Csm

9 Type III-A CRISPR-Cas systems defend prokaryotes against

10 dition, mutations in the active sites of the type III-A RNases Csm3 and Csm6 lead to the accumulation

11 should be considered as primary therapy for type III achalasia; 4) if the expertise is available, PO

12 secretion by suppressing fluid transport in type III acini.

13 ding structures opening towards the lumen in type-III acini.

14 egulation (p < 0.01) with increased Collagen type III and increased expression of several apoptosis r

15 When mutations in the fibronectin type III and kinase domains of EPHB1 were compared with

16 saliva formation, mediated by Na/K-ATPase in type III and type II acini, is followed by a dopamine-in

17 Here we test the ability of 200 type III and type IV effector proteins from six Gram-neg

18 rentially expressed during infection and the type III and VI secretion systems were highly expressed

19 hydrocarbon-dominated organic matter types (types III and IV; mainly land plant, metamorphosed or de

20 , acquired angioedema, hereditary angioedema type III, and angiotensin converting enzyme inhibitor-in

21 The effector complex of the Type III-B Cmr system cleaves invader RNAs recognized by

22 The Sulfolobus islandicus type III-B Cmr-alpha system targets invading nucleic aci

23 erranean seagrass meadows, we found that the type III-B machinery co-opts type I-F CRISPR-RNAs.

24 In the Type III-B system, the Cmr effector complex has been fou

25 type I-F spacers by a horizontally-acquired type III-B system.

26 A second system (type III-B) is broadly capable of acquiring spacers in e

27 otic activity, and osteotomy site healing in type III bone and high endogenous Wnt signaling.

28 ) bone versus more trabeculated, cancellous (type III) bone.

29 yses to identify and characterize type I and type III bones in murine jaws.

30 IL-18 are cell-specific and were observed in Type III but not in Type I/II neurons.

31 ylated viral promoters that are expressed in type III (but not type I) latency.

32 -dentin area showed significant increases in type III, but not in types I or II cases.

33 This evolved into type III by aggravating both mechanical substrates.

34 sinaemia type I into the benign tyrosinaemia type III by deleting Hpd (hydroxyphenylpyruvate dioxigen

35 ic responses could explain why a minority of type III cells (34%) had AI salt responses but lacked an

36 All AI type III cells had osmotic responses to cellobiose, whic

37 he transduction machinery for salty taste in type III cells is sensitive to anion size.

38 se responses were significantly larger in AI type III cells that did not exhibit the anion effect.

39 The sour sensing cells, Type III cells, release serotonin (5-HT) in response to

40 ed to neuronal function were up-regulated in type III cells.

41 type II cells and physiologically identified type III cells.

42 ctyostelium and mutant cells lacking ChdC, a Type III CHD protein ortholog.

43 Type III CHDs are required for multicellular development

44 opment, establish an in vivo function of CHD Type III chromatin remodeling proteins in this process,

45 ypes of ependymal cilia, type-I, type-II and type-III classified based upon their beating frequency,

46 In many prokaryotes, type III clustered regularly interspaced short palindrom

47 effect by increasing the amount of refolded type III collagen in vitro and FKBP19 seems to interact

48 agen, the unhydroxylated quarter fragment of type III collagen, and synthetic peptides as substrates.

49 preferences of these PPIases in vitro using type III collagen, the unhydroxylated quarter fragment o

50 icated cracks, a combination of a Type I and Type III cracks, which may or may not be confluent with

51 Although most type I and type III CRISPR systems require four or more distinct pr

52 In several type III CRISPR systems, Cas1 is naturally fused to a re

53 I and II systems, the relaxed specificity of type III CRISPR-Cas targeting provides robust immune res

54 22 in strain 26695, encodes a N(6)-adenosine type III DNA methyltransferase.

55 activating mutation in the fibronectin-like type III domain of the extracellular region of CSF3R (W3

56 -binding proteins based upon the fibronectin type III domain, and we find that variations in sequence

57 F splice variants 1, 2, 4, 6 and fibronectin type III domain-containing protein 5 (FNDC5) mRNA levels

58 en the membrane-proximal (third) Fibronectin type III domains (Fn3) of Tie2.

59 ose cryptic FN-FN binding sites buried in FN Type III domains.

60 II (e.g. the Tas1r genes, Plcb2, Trpm5) and type III (e.g. Pkd2l1, Ncam, Snap25) taste cells.

61 EBV infection and suggest that TET2 promotes type III EBV latency in B cells with an ABC or naive phe

62 ed Xam strains in which individual predicted type III effector (T3E) genes were mutated and applied m

63 interaction between the Pseudomonas syringae type III effector AvrPtoB and NPR1.

64 ttom-up approach, showing that the bacterial type III effector AvrRxo1 of plant pathogens is an authe

65 Finally, we show that the type III effector IpgB1 from Shigella flexneri may bind

66 We isolated Response to the bacterial type III effector protein HopBA1 (RBA1), a gene that enc

67 HopAF1 is a type III effector protein of unknown function encoded in

68 A screen for type III effector proteins from Pst for their ability to

69 plex contact host cell membranes and deliver type III effector proteins.

70 from an extensive phylogenetic analysis, and type III effector translocation and host cell invasion a

71 viously unstudied Pseudomonas syringae (Psy) type III effector, HopBB1, interacts with TCP14 and targ

72 y to delete the coding sequences for a known type III effector.

73 DC3000 (Pst DC3000), demonstrating that the type-III effector HopG1 is required for pathogen-induced

74 oduce a computational method that identifies type III effectors by combining homology-based inference

75 h is required for efficient translocation of type III effectors into host cells.

76 Most plant bacterial pathogens rely on type III effectors to cause diseases.

77 erstanding of the basis of host specificity, type III effectors, microbe-associated molecular pattern

78 The spike resonance of these phasic-firing (type III excitable) MSO neurons and of the model is of p

79 A marked shift in collagen predominance from type III (fetal/early wound) to type I (adult/mature) wa

80 PavA and PavB target at least 13 out of 15 type III fibronectin domains as demonstrated in ligand o

81 t antigen to be MrkA, a major protein in the type III fimbriae complex, and showed that these serotyp

82 a highly conserved region of the fibronectin type III (FN3) domain of the receptor tyrosine kinase Ep

83 C2 type (IgC2) domains and four fibronectin type III (FnIII) domains that are shared with many other

84 is mediated by membrane-proximal fibronectin type III (FNIII) domains that were omitted in previous s

85 ructural switch within its first fibronectin type III (FnIII-1) domain to control RbmA structural dyn

86 d-optimal temperatures, predators may have a type III functional response, and prey carrying capacity

87 Reducing the excitatory input on Type III GABAergic neurons, IL-18 can increase the firin

88 it feeding by inhibiting the activity of BST Type III GABAergic neurons.

89 sentative of the protective response against type III GBS polysaccharide.

90 ram-positive group B Streptococcus, capsular type III (GBS-III) bacteria resulted in augmented serum

91 ncing similar to what is seen in EBV latency type III genomes.

92 ally (occluso-gingival) oriented cracks; and Type III - hybrid or complicated cracks, a combination o

93 skin, but the mechanisms that regulate this type III hypersensitivity process remain poorly understo

94 Small immune complexes cause type III hypersensitivity reactions that frequently resu

95 ms made with IBPs (both from winter rye, and type III IBP) had aggregates of ice crystals that entrap

96 ound that adding recombinantly produced fish type III IBPs at a concentration 3mg.L(-1) made ice crea

97 pha/beta) controls systemic replication, and type III IFN (IFN-lambda) controls MNV persistence in th

98 Type I IFN (IFN-alpha/beta) and type III IFN (IFN-lambda) function at the epithelial lev

99 se to infection both in vitro and in vivo is type III IFN and acid labile.

100 IFN-lambda4 is a unique type III IFN because it is produced only in individuals

101 Since these miRNAs can suppress type III IFN family members, these data collectively def

102 The mechanisms that regulate type III IFN gene expression tracked with those that pro

103 However, the roles of type I and type III IFN in restricting human enteric viruses are po

104 has a positive role in enhancing type I and type III IFN production.

105 Early after HRV infection, low levels of type III IFN protein activate IFN-stimulated genes.

106 se replication-competent HRV antagonizes the type III IFN response at pre- and posttranscriptional le

107 overned by genetic polymorphisms that affect type III IFN signaling and virus-specific cellular immun

108 tion, with type I IFN being more potent than type III IFN, suggesting that extraepithelial sources of

109 In addition, we found that fetuses lacking type III IFN-lambda signaling had increased ZIKV replica

110 tional pathway induced by HRV infection is a type III IFN-regulated response.

111 alpha/beta) and the more recently identified type III IFNs (IFN-lambda) function as the first line of

112 Type III IFNs (IFN-lambdas) are secreted factors that ar

113 hoblasts through the constitutive release of type III IFNs (IFNlambda1 and IFNlambda2) and become res

114 IRF1 is necessary for the expression of type III IFNs (IFNLs 1 and 2/3).

115 ter of pregnancy also constitutively release type III IFNs and use these IFNs in autocrine and paracr

116 Type III IFNs are important mediators of antiviral immun

117 ly expressed from TLRs present on endosomes, type III IFNs could be induced by TLRs that reside at th

118 IFN-lambda4 acted faster than other type III IFNs in inducing antiviral genes, as well as ne

119 on and new human models to study the role of type III IFNs in the vertical transmission of ZIKV and o

120 hepatocytes (PHHs) treated with recombinant type III IFNs or infected with Sendai virus to model acu

121 ctions in cell-intrinsic antiviral immunity, type III IFNs protect epithelial barrier integrity, an a

122 Lambda interferons (IFNlambdas) or type III IFNs share homology, expression patterns, signa

123 Type III IFNs were originally identified as a novel liga

124 ormed in 47.2% (type II) and apical closure (type III) in 38.9% cases.

125 Gigot type III individuals scored numerically higher than type

126 through a second messenger generated by the type III interference complex.

127 zontal uptake and maintenance of promiscuous type III interference modules that supplement existing h

128 ay, suppress IFNL2 and IFNL3, members of the type III interferon (IFN) gene family, to support viral

129 PHT cells constitutively release the type III interferon (IFN) IFNlambda1, which functions in

130 Type III interferon (IFNlambda) and type I IFN (IFNalpha

131 L-10R family and highlight the plasticity of type III interferon signaling and its therapeutic potent

132 Type III interferons (IFN-lambda) control enteric viral

133 Type III interferons (IFN-lambdas) signal through a hete

134 ctors, including the constitutive release of type III interferons (IFNs).

135 se, including strong induction of type I and type III interferons (IFNs).

136 This in turn stimulates production of type III interferons and hence enhances tumour antigen p

137 We focus here on desmin, a type III intermediate filament, which is specifically ex

138 ncept of sphincter of Oddi dysfunction (SOD) type III is discarded.

139 pe 2-oriented membrane-retained stub of NRG1 type III is further processed by signal peptide peptidas

140 Thus, NRG1 type III is the first protein substrate that is not only

141 Neuregulin 1 type III (NRG1 type III) is a major physiological substrate of beta-sec

142 lar resistance, proteolysis, quorum sensing, Type III/IV secretion systems, phages and toxins in the

143 Type I (alpha and beta) and type III (lambda) IFNs are induced upon viral infection

144 H3 at lysine 4) and H3 acetylation at Cp in type III latency and Qp in type I latency, as well as an

145 e transcripts are regulated similarly to EBV type III latency genes and that TET2 protein is a cofact

146 cofactor of EBNA2 and coregulator of the EBV type III latency program and DNA methylation state.IMPOR

147 n correlate with the highly demethylated EBV type III latency program permissive for expression of EB

148 a germinal center (GC) B cell phenotype, and type III latency with an activated B cell (ABC) phenotyp

149 e whether EBV enters the highly transforming type III latency, versus the more restricted type I late

150 to convert EBV-infected cells from type I to type III latency.

151 vation from lymphoblastoid cells (LCLs) with type III latency.

152 ients in Europe are also consistent with the type III lineage.

153 The basic defect in long-QT syndrome type III (LQT3) is an excessive inflow of sodium current

154 lvability, while non-neutral correlations of type iii) may instead facilitate evolutionary exploratio

155 hase-variable methylation by both Type I and Type III methyltransferases is associated with altered g

156 ed MegaSTAR to identify pairs of fibronectin type III monobodies for three human proteins.

157 Expression of type III neuregulin-1 (TIIINRG1) in induced pluripotent

158 Interestingly, IL-18-sensitve Type III neurons were recorded in the juxtacapsular BST,

159 n-Type III-nitride nanowires decorated with Ru sub-nanoclu

160 Both type I and type III NRG1 improves deficits in the Morris water-maze

161 II) were conditionally ablated, leaving the type III Nrg1 intact.

162 that soluble ectodomains of both type I and type III NRG1 significantly increased expression of Abet

163 test this possibility, full-length type I or type III NRG1 was overexpressed via lentiviral vectors i

164 Neuregulin 1 type III (NRG1 type III) is a major physiological substr

165 Neuregulin 1 type III (Nrg1III) and laminin alpha2beta1gamma1 (Lm211)

166 B cells support a highly transforming form (type III) of viral latency; however, long-term EBV infec

167 Hereditary sensory and autonomic neuropathy type III, or familial dysautonomia [FD; Online Mendelian

168 opsis showed that exposure to LS upregulated type III peroxidase genes, of which some are involved in

169 led by NADPH oxidases as well as by secreted type III peroxidases has a great impact on cell wall pro

170 Type III phosphatidylinositol 4-kinase (PI4KIIIbeta) is

171 istical association between strains from the type III phylogenetic lineage and PMH lesions (P = 0.001

172 Chalcone synthase (CHS), a type III plant polyketide synthase, is critical for flav

173 oding proteins of several families including type-III polyketide synthases, hydrolases, and cytochrom

174 ecies (type II), Staphylococcus epidermidis (type III), Porphyromonas and Peptoniphilus species (type

175 ganization of the collagen network, collagen type III predominance, and lack of collagen fiber insert

176 various substrates, thus classifying it as a type III PRMT.

177 RNA polymerase III (RNAP III) type III promoters (U6 or H1) are typically used to driv

178 Using a high-throughput assay for type III protein secretion in Salmonella enterica serova

179 Type III protein secretion machines have evolved to deli

180 Type III protein secretion systems have specifically evo

181 The Chromodomain-Helicase-DNA binding (CHD) Type III proteins are a subfamily of SWI2/SNF2 proteins

182 Transforming growth factor beta type III receptor (TbetaRIII/betaglycan) is a transmembr

183 ly secreted from cardiomyocytes, as were the type III repeat (T3R) and TSP-C domains, while the LamG

184 tural comparisons revealed that the targeted type III repeat epitopes cluster on the inner strands of

185 ing matricryptic RWRPK sequence in the first type III repeat of fibrillar fibronectin.

186 icryptic heparin-binding region of the first type III repeat of fibrillar FN (FNIII1H) mediates vasod

187 FnBPs recognize similar peptides in targeted type III repeats.

188 i) metal coordination to the organic ligand (type III), respectively.

189 In contrast, type III responses convey stability at intermediate temp

190 a combination of random fragmentation and a type III restriction enzyme to derive a densely covering

191 tion system as a molecular syringe to inject type III secreted effector (T3SE) proteins in plants.

192 the reactive oxygen species burst using two type III secreted effector proteins, ExoS and ExoT.

193 e roles of toxins, type II secreted enzymes, type III secreted effectors and motility as well as thei

194 wn about the prerequisites for deployment of type III secreted proteins during infection.

195 cytosolic interface of the membrane spanning type III secretion 'injectisome'.

196 The type III secretion (T3S) injectisome is a specialized pr

197 Type III secretion (T3S), a protein export pathway commo

198 amylovoran, and had increased expression of type III secretion (T3SS) genes in vitro.

199 , a direct physiologic role for the Shigella type III secretion apparatus (T3SA) in mediating phagoso

200 recisely with the activation of the Shigella type III secretion apparatus, thus evidencing injectisom

201 free cytosolic complexes, which include the type III secretion ATPase, constitute a highly dynamic a

202 g a microcompartment shell protein (PduA), a type III secretion effector protein (SteA), and a metabo

203 Here we report that the Salmonella type III secretion effector, SipA, is responsible for P-

204 The ExoU type III secretion enzyme is a potent phospholipase A2 s

205 will be instrumental for the development of type III secretion inhibitors.

206 ation and characterization of the Salmonella type III secretion machine in live bacteria by 2D and 3D

207 situ structure of the Salmonella Typhimurium type III secretion machine obtained by high-throughput c

208 reviously unknown effectors, suggesting that type III secretion may have evolved prior to the archaea

209 epends in part on its pathogenicity island 2 type III secretion system (SPI-2 T3SS), which is require

210 inflammasome upon sensing components of the type III secretion system (T3SS) and flagellar apparatus

211 ne and expression dose of the antiphagocytic type III secretion system (T3SS) and induces functions c

212 opathogenic Escherichia coli (EPEC) uses the type III secretion system (T3SS) effector EspL to degrad

213 . Typhimurium pathogenicity island-1 (SPI-1) type III secretion system (T3SS) effectors and transloca

214 P. aeruginosa expresses a type III secretion system (T3SS) needle complex that ind

215 The SPI-2 type III secretion system (T3SS) of intracellular Salmon

216 e receptors sense host-cell targeting by the type III secretion system (T3SS) of pathogenic Yersinia.

217 ny pathogenic Gram-negative bacteria use the type III secretion system (T3SS) to deliver effector pro

218 tive pathogens infect eukaryotes and use the type III secretion system (T3SS) to deliver effector pro

219 Citrobacter rodentium uses a type III secretion system (T3SS) to induce colonic crypt

220 Many bacteria use a type III secretion system (T3SS) to inject effector prot

221 gative pathogens, Shigella rely on a complex type III secretion system (T3SS) to inject effector prot

222 EHEC employs a type III secretion system (T3SS) to translocate 50 effec

223 dosomal membrane damage by components of the type III secretion system (T3SS) translocon.

224 rV is an essential part of the P. aeruginosa type III secretion system (T3SS), and its oligomeric nat

225 and regulatory components of the P. syringae type III secretion system (T3SS), essential for coloniza

226 m-negative bacteria secrete proteins using a type III secretion system (T3SS), which functions as a n

227 e characterize a regulatory node involving a type III secretion system (T3SS)-exported protein, BtrA,

228 ence effectors into the cell cytoplasm via a type III secretion system (T3SS).

229 d P. aeruginosa virulence determinant is the type III secretion system (T3SS); the production of T3SS

230 is organism requires a horizontally acquired type III secretion system (T3SS2) to infect the small in

231 B, are required for activating the virulence type III secretion system 2 in response to bile salts.

232 he epithem and is actively suppressed by the type III secretion system and its effector proteins.

233 syringae and Xanthomonas campestris, use the type III secretion system as a molecular syringe to inje

234 's immune response, Y. enterocolitica uses a type III secretion system consisting of an injectisome a

235 The Pseudomonas aeruginosa type III secretion system delivers effector proteins dir

236 fication of two homologous Shigella flexneri type III secretion system effector E3 ligases IpaH1.4 an

237 Exoenzyme Y (ExoY) is a type III secretion system effector found in 90% of the P

238 tium strains bearing deletions in individual type III secretion system effector genes to determine wh

239 The type III secretion system effector protein NleE from ent

240 Y. pestis type III secretion system effectors YopJ and YopM can in

241 mbrella term given to E. coli that possess a type III secretion system encoded in the locus of entero

242 leum, a virulence process carried out by the type III secretion system encoded within Salmonella path

243 depends on effector proteins secreted by its type III secretion system for the pathogenesis of plants

244 Type III secretion system is a key bacterial symbiosis a

245 er Gram-negative bacterial pathogens, uses a type III secretion system to deliver multiple proteins,

246 domonas syringae secretes effectors from its type III secretion system to infect plants.

247 It deploys a type III secretion system to inject effector proteins in

248 hogens use a syringe-like apparatus called a type III secretion system to inject virulence factors in

249 effectors into host cells via a prototypical type III secretion system to promote pathogenesis.

250 In many Gram-negative bacteria, the type III secretion system transports effector proteins i

251 at the introduction of a functional Shigella type III secretion system, but none of its effectors, in

252 -silenced plants are more susceptible to the type III secretion system-deficient bacterial strain Pse

253 ets identified the mRNA for the regulator of type III secretion system.

254 s across its vacuolar membrane via the SPI-2 type III secretion system.

255 ctors delivered into plant cells through the type III secretion system.

256 Type III Secretion Systems (T3SS) are complex bacterial

257 Flagellar type III secretion systems (T3SS) contain an essential c

258 Type III secretion systems (T3SSs) are essential devices

259 Type III Secretion Systems (T3SSs) are structurally cons

260 Type III secretion systems (T3SSs) inject bacterial effe

261 Salmonella species utilize type III secretion systems (T3SSs) to translocate effect

262 inject effector proteins into host cells via type III secretion systems (T3SSs).

263 e inner rod and needle proteins of bacterial type III secretion systems (T3SSs).

264 he injectisome (iT3SS) and flagellar (fT3SS) type III secretion systems are 2 virulence factors assoc

265 Type III secretion systems are complex nanomachines used

266 sponse, attaching and effacing pathogens use type III secretion systems to introduce effectors target

267 e homology to ring-forming proteins found in type III secretion systems, assembles into an oligomeric

268 quired the presence of functional Salmonella type III secretion systems.

269 e intermembrane space, as has been found for type III secretion systems.

270 of proteins involved in central metabolism, type III secretion, and protein synthesis were associate

271 w that Pst inhibits proteasome activity in a type III secretion-dependent manner.

272 tial mechanism involved in the regulation of type III secretion.

273 dant to IcsA; its activity is independent of type III secretion.

274 This mode of protein export is termed type-III secretion (T3S).

275 d action of the cargo-conducting part of the type-III secretion apparatus.

276 isomes of gram-negative pathogens, is termed type-III secretion.

277 functional analyses, may help to explain why type III strains are associated with PMH.

278 gions that are specific for, or absent from, type III strains compared to other phylogroups.

279 the natural history of mucopolysaccharidosis type III syndromes, neurocognitive progression was impro

280 lfataricus has two divergent subtypes of the type III system (Sso-IIID and a Cmr7-containing variant

281 Type III systems (Cmr, Csm) have been shown to cleave RN

282 As has been observed for other Type III systems, Cmr eliminates plasmid invaders in Pyr

283 lex and provide a unifying mechanism for all Type III systems.

284 mild post-systolic shortening (n = 35); and type III: systolic stretching with large post-systolic s

285 e information involves communication between Type III taste cells and 5-HT3 -expressing afferent nerv

286 um imaging, we identified AI salt-responsive type III taste cells and demonstrated that they compose

287 o separate populations of AI salt-responsive type III taste cells distinguished by their sensitivity

288 bsence of TPs, many (66%) AI salt-responsive type III taste cells still exhibited the anion effect, d

289 chanisms could underlie AI salt responses in type III taste cells, one of which may contribute to the

290 ly contact and receive synaptic contact from Type III taste cells.

291 e mechanism contributes to salt responses in type III taste cells.

292 ular PAR levels were up to 2-fold greater in type III than type I latently infected EBV B cells.

293 study, we show that a representative of fold type III, the Escherichia coli alanine racemase (ALR), i

294 ling and maturation with a shift in collagen type III to I.

295 We show that the type III transforming growth factor beta (TGF-beta) rece

296 Because of the hairpin nature of NRG1 type III, two membrane-bound stubs with a type 1 and a t

297 Usher syndrome type III (USH3) characterized by progressive loss of vis

298 re identified from water buffalo and a third type (III) was isolated from goat.

299 of structural staged mutation carriers were type III, whereas a large proportion of both electrical

300 ine (Type II) or manifest as a chronic form (Type III) with a wide spectrum of neurological signs.